EP 0930882 A2 19990728 - PREVENTION OR TREATMENT OF TYPE 2 DIABETES OR CARDIOVASCULAR DISEASE WITH PPAR MODULATORS
Title (en)
PREVENTION OR TREATMENT OF TYPE 2 DIABETES OR CARDIOVASCULAR DISEASE WITH PPAR MODULATORS
Title (de)
VORBEUGUNG ODER BEHANDLUNG VON TYP 2 DIABETES ODER KARDIOVASKULÄRER ERKRANKUNG MIT PPAR MODULATOREN
Title (fr)
PREVENTION OU TRAITEMENT DE DIABETES NON INSULINODEPENDANTS OU DE MALADIES CARDIOVASCULAIRES AVEC DES MODULATEURS PPAR
Publication
Application
Priority
- US 9713605 W 19970801
- US 2294996 P 19960802
Abstract (en)
[origin: WO9805331A2] This invention relates to methods and compositions for the prevention and treatment of Type 2 diabetes and cardiovascular disease with diabetic or pre-diabetic conditions or symptoms associated therewith using both a PPAR gamma agonist and a PPAR alpha agonist or a compound which activates both PPAR gamma and PPAR alpha . A preferred PPAR gamma agonist is a thiazolidinedione compound, including BRL 49653, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and congeners, analogs, derivatives and pharmaceutically acceptable salts thereof. A preferred PPAR alpha agonist is a fibrate compound including gemifbrozil, fenfibrate, bezofibrate, clofibrate, ciprofibrate, and analogs, derivatives and pharmaceutically acceptable salts thereof.
IPC 1-7
IPC 8 full level
A61K 31/196 (2006.01); A61K 31/425 (2006.01); A61K 31/44 (2006.01); A61K 38/28 (2006.01)
CPC (source: EP)
A61K 31/196 (2013.01); A61K 31/425 (2013.01); A61K 31/44 (2013.01); A61K 38/28 (2013.01)
C-Set (source: EP)
Citation (search report)
See references of WO 9805331A2
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE
DOCDB simple family (publication)
WO 9805331 A2 19980212; WO 9805331 A3 19980507; AU 4050797 A 19980225; EP 0930882 A2 19990728
DOCDB simple family (application)
US 9713605 W 19970801; AU 4050797 A 19970801; EP 97938101 A 19970801